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Materials and methods 
Construction of a modified bicoid promoter: 
A bicoid promoter fragment was amplified from genomic DNA with primers Bic-
5 5’- GGC CTC GAG TTA GAT CTC AAT TGT GCC ATC TCT ACA TCT CTT CGC 
TCA TCC CTA AAT AAA AGA ATG AAC ATC GAG GGA GG and Bic-3 5’ GGC 
CAA TTG GGC GGC GGT TGC GCC GTT TTC C, cut with Xho1 and EcoRI [all 
restriction enzymes provided by New England Biolabs (NEB), Beverly MA], and ligated 
into pGMR (1) cut with the same enzymes. Two Serendipity (Sry) binding sites [CGC 
TCA TCC CTA AAT and GTG CCA TCT CTA CA (2)] were placed 5’ to the bicoid 
promoter in order to enhance maternal expression levels. Primers 4bic-1 5’- GGC CTC 
GAG TTA GAT CTC AAT TGT GCC ATC TCT ACA TCT CTT CGC TCA TCC CTA 
AAT AAA AGA ATG AAC ATC GAG GGA GG and Bic-3 were annealed with the 
bicoid promoter fragment generated above and PCR carried out (Fig. S4A). This product 
was cloned into pGMR as above, generating pSry-Bic-GMR. 
 
Construction of miRNAs targeting myd88. 
The Drosophila miRNA mir6.1 is illustrated in Fig. S4B. The Drosophila miRNA 
mir6.1 stem-loop precursor and surrounding sequences is illustrated to the left, with the 
mature miRNA indicated in red. Processing sites for Drosha and Dicer are indicated 
(arrows). 22bp sequences corresponding to mature mir6.1 were replaced with sequences 
perfectly complementary to sequences from the myd88 5’UTR, generating two new 
miRNAs, mir6.1-myd88-1 and mir6.1-myd88-2. Two sites in the myd88 transcript were 
targeted to minimize the possibility that mRNA secondary structure would prevent the 
miRNA-RISC complex from being able to bind and cleave the mRNA. The use of 
multiple miRNAs targeting a common transcript, but at distinct positions, also provides a 
method for limiting the possibility that a single mutational event (in either the miRNA or 
the target sequence) will lead to a loss of toxin efficacy. Myd88 mRNA sequences are 
indicated in black. The sites in myd88 that are targeted are Myd88-1 CGA TCG GAA 
AAC TCG AAA AAA T and Myd88-2 TCA CGC GCT TCA TCG TTT TAT T (Fig. 
S4C). To generate a mir6.1 stem-loop backbone that generates a mature miRNA 
complementary to one or the other of these target sites we annealed pairs of primers. For 
example, to make a miRNA that targets myd88-1, primers Myd881-1 and Myd881- 2 (D-
dMyd881-1: 5'-GGC AGC TTA CTT AAA CTT AAT CAC AGC CTT TAA TGT CGA 
TCG GAA AAC TCG AAA ACA TTA AGT TAA TAT ACC ATA TC and D-
dMyd881- 2: 5'-AAT AAT GAT GTT AGG CAC TTT AGG TAC CGA TCG GAA 
AAC TCG AAA AAA TTA GAT ATG GTA TAT TAA CTT AAT GT) were annealed 
and filled in using PCR (Fig. S4C). This product was then amplified using primers Mir6 
5’ EcoRI/BglII (5'-GGC GAA TTC CGC CAG ATC TTT TAA AGT CCA CAA CTC 
ATC AAG GAA AAT GAA AGT CAA AGT TGG CAG CTT ACT TAA ACT TA) and 
Mir6 3’ BamHI/NotI (5' GGC CGC GGC CGC ACG GAT CCA AAA CGG CAT GGT 
TAT TCG TGT GCC AAA AAA AAA AAA AAT TAA ATA ATG ATG TTA GGC 
AC). These primers add mir6.1 flanking sequences that are thought to promote miRNA 
processing, as well as several restriction sites (Fig. S4C). A miRNA that targets myd88-2 
was generated similarly, beginning with primers Myd882-1 GGC AGC TTA CTT AAA 
CTT AAT CAC AGC CTT TAA TGT TCA CGC GCT TCA TCG TTT TCT TTA AGT 
TAA TAT ACC ATA TC and Myd882-2 AAT AAT GAT GTT AGG CAC TTT AGG 
TAC TCA CGC GCT TCA TCG TTT TAT TTA GAT ATG GTA TAT TAA CTT AAA 
GA. PCR products were purified with Qiagen (Valencia, CA) PCR purification columns, 
and then digested with enzymes. For dMyd88-1 these were EcoRI and BamHI, for 
dMyd88-2 BglII and NotI. Digested products were then ligated into sry-bic-GMR cut 
with EcoRI and NotI, generating pBic-mir6.1-myd88. The structure of this construct is 
shown in Fig. S4D. 
 
Zygotic promoter and myd88 antidote rescue construct: 
A 500 bp fragment of DNA containing the transient, early zygotic bnk promoter 
(3) was amplified from genomic DNA using primers Bnk 5’ XhoI (5'-GGC CTC GAG 
TAT TTC ACA AAT TCA ATT TTA ATA TTT AAG) and Bnk3’ EcoRI (5'-GGC GAA 
TTC GTT GAC GGT TGA AGT ACG AAT GTG CTG T), cut with XhoI and EcoRI 
and inserted into similarly cut pGMR, generating P-BNK. The myd88 coding region was 
amplified from a cDNA library using primers myd88-5 (5’- GGC GAA TTC ATG CGC 
CCT CGA TTT GTA TGC CAT C and myd88-3 (5’- GGC GCG GCC GCT CAG CCC 
GGC GTC TGC AGC TTC), cut with EcoRI and NotI, and ligated into similarly cut P-
BNK, generating P-BNK-dMYD88 (Fig. S5A). Note that because this myd88 transcript 
lacks a 5' UTR present in the endogenous myd88 transcript, it is not silenced by mir6.1-
myd88-1 or mir6.1-myd88-2, which target the myd88 5' UTR. 
 
Generation of MedeaMyd88: 
P-BNK-dMYD88 (Fig. S5A) was cut with XhoI and 5’ ends were dephospholated 
with Calf Intestinal Alkaline Phosphatase (NEB, Beverly MA). A gypsy insulator-
containing DNA fragment was amplified from genomic DNA using a 5’ primer (gypsy 
5’) that contained a number of restriction enzyme target sites (SalI, HpaI, AvrII, NheI, 
SpeI, KpnI, BglII) (5’- GGC GTC GAC GTT AAC CTA GGC TAG CAC TAG TGG 
TAA CCC CGA GAT CTT CAC GTA ATA AGT GTG CGT TGA ATT TAT TCG C) 
and a second primer (gypsy 3’), which contains an XhoI site, (5’- GGC CTC GAG AAT 
TGA TCG GCT AAA TGG TAT GGC AAG AAA AG). This PCR fragment was cut 
with SalI and XhoI and ligated into XhoI cut P-BNK-dMYD88. This created Pgypsy- 
BNK-dMYD88 (Fig. S5B), which was cut with AvrII and dephosphorylated with Calf 
Intestinal Alkaline Phosphatase. The modified bicoid promoter and myd88-targeting 
miRNAs in pBic-mir6.1-myd88 (Fig. S4D) were amplified using primers 4 BIC Myd 1+2 
5’ AvrII- 5' GGC CCT AGG GTC GAG TTA GAT CTC AAT T and 4 BIC Myd 1+2 3’ 
HpaI /SpeI/ Nhe- 5' GGC GTT AAC ACT AGT GCT AGG GCC TTC TAG ACC CCG 
GCC GC. The PCR product was cut with AvrII and NheI and ligated into AvrII cut P-
gypsy-BNK-dMYD88. One plasmid product, designated P-bicoid-myd88RNAi-gypsy-
BNK-dMYD88, was selected in which the bicoid and myd88 promoters were oriented so 
as to transcribe in opposite directions (Fig. S5C). 
 
Generation of Medeamyd88-int: 
The plasmid P-Bnk-dMyd88 was cut was cut with EcoRI and NotI, the vector 
purified and then ligated with PCR fragments dMyd88 exon 1/intron 1(EcoRI, SpeI) and 
intron 1/ exon2 (SpeI, NotI), generating P-Bnk-dMyd88-intron. PCR fragment dMyd88 
exon 1/intron contains dMyd88 exon 1and a 5’ splice site. This fragment was amplified 
by PCR with primer Myd88 EcoRI 5’ (5'-GGC GAA TTC ATG CGC CCT CGA TTT 
GTA TGC C) and Myd 88 exon 1 /intron SpeI /NheI 3’ (5'- GGC ACT AGT GGC CGC 
TAG CAG CGA CTA CCA TAA GTA AAA AAT AGT TAA TGC CTA CCC AGA 
TTC TCC TGG ATA TCG TCG CAG). The second PCR fragment, dMyd88 intron 1/ 
exon2, contains intron 1, a pyrimidine-rich trait and 3’ splice site as well as the 3' exons 
of dMyd88 derived from the cDNA. This fragment was amplified by PCR with primers 
myd88-EXON2–intron-SpeI-5 (5'- GGC ACT AGT TAG TAA AAC TGT TTT AAT 
TTT GCT CTC CTC AAA AGC CAA GGA CAC CCA GCG CTT CAT CAT G) and 
myd88-NotI-3 (5'- GGC GCG GCC GCT CAG CCC GGC GTC TGC AGC TTG C). P-
Bnk-dMyd88-intron was cut with SpeI, which cuts within the intron. The product was 
dephosphorylated with Calf Intestinal Alkaline Phosphatase according to the 
manufacturers instructions (NEB, Beverley MA) and ligated with a PCR product 
containing the modified bic promoter and the Myd88- targeting miRNAs. Primers used 
were 4 BIC Myd 1+2 5’ SpeI, which also contains a consensuses branch point site GAT 
TAG ATG, (5' GGC ACT AGT TAT TGA TTA GAT GTC GAG TTA GAT CTC AAT 
T) and 4 BIC Myd 1+2 3’ NheI (5'- GGC GCT AGC GGC CTT CTA GAC CCC GGC 
CGC). The final product was designated as Pw+Medeamyd88-int. 
 
Transgenesis and Population cage experiments: 
Germline transformants were generated in a w1118 background using standard 
techniques, by Rainbow Transgenic Flies, Inc (www.rainbowgene.com, Newbury Park, 
CA). The exact origin of the chromosomes present in the w1118 strain used for 
transgenesis and population replacement experiments, and the relationship of these 
chromosomes to those present in the OR strain, is unknown. The second and third 
chromosomes were isogenized in a w1118 background in the early 1990s as a prelude to a 
large mutagenesis screen for regulators of Ras pathway signaling (6). The stock has been 
maintained continuously in the laboratory since then. All fly experiments were carried 
out at 25oC, ambient humidity in 250 ml bottles containing Lewis medium (4) 
supplemented with live dry yeast. Fly rearing was carried out in a light tight chamber 
placed in an incubator or in a darkened incubator. In a first set of experiments (three 
green lines in Fig. 1E,F), three populations of 50 males heterozygous for Medeamyd88-1 
(w1118/Y; Pw+Medeamyd88-1/+) were each crossed with 50 w1118 females in separate bottles. 
In a second set of experiments (four blue lines in Fig. 1E, F) 25 wildtype (+/+) males and 
25 homozygous Medeamyd88-1/ Medeamyd88-1 males were crossed with 50 w1118 females in 
separate bottles. For both sets of experiments flies were allowed to lay eggs for four days, 
after which adults were removed. Progeny were allowed to develop, eclose and mate for 
another 10 days. All adult progeny were collected at this single timepoint and their 
genotypes determined using eye color as a marker (no Medea, w1118 = white eyed; 
Medeamyd88-1/+ = yellow/orange eyed; Medeamyd88-1/ Medeamyd88-1 = darker red eyed). 
Note that adult progeny continued to eclose after the time of collection. These were not 
counted or transferred into the subsequent generation population. Numbers of adults 
scored per population per generation ranged between 102 and 601 (mean 333; s.d.105). 
Following counting, progeny were transferred to fresh bottles and allowed to lay eggs for 
four days, and the cycle repeated.  
In a second set of population cage experiments, Medeamyd88-1 was first introduced 
into a w+ background in order to decrease the possibility that Pw+ expression from the 
vector carrying Medeamyd88 was providing these animals with an unknown (vision-
independent) fitness advantage. Females homozygous for Medeamyd88-1 were mated with 
Oregon R (OR) males, which carry a wildtype copy of the w gene at the endogenous 
locus on the X chromosome. Progeny males, which are w+/Y; Medeamyd88-1 were then 
mated as above to OR virgin females to initiate the population cage experiments. The 
presence of the endogenous w+ gene completely prevents direct identification of 
Medeamyd88-1-bearing individuals based on eye color, since the endogenous w+ gene is 
expressed at very high levels compared with the Pw+ in our transformed strain. We 
determined genotypes at the end of the 12th generation in the following way. 200 males 
from each population were mated singly in vials with w1118 females. All male progeny 
inherit the w1118 chromosome from their mothers (making them w1118 with respect to the 
endogenous locus on the X chromosome). However, those males that carry one copy of 
Medeamyd88-1 give rise to 50% red-eyed progeny, while those homozygous for 
Medeamyd88-1 give rise to all red-eyed progeny. In each of the three populations the % of 
non-element-bearing males was less than 1%: population #1 = 0/200 +/+, 30/200 
Medeamyd88-1/+, 170/200 Medeamyd88-1/ Medeamyd88-1; Population #2 = 1/200 +/+, 
67/200 Medeamyd88-1/+, 132/200 Medeamyd88-1/ Medeamyd88-1; Population #3 = 0/200 
+/+, 58/200 Medeamyd88-1/+, 142/200 Medeamyd88-1/ Medeamyd88-1. Note that the OR 
genetic background into which Medeamyd88-1 was introduced should be assumed to be 
distinct from that of the w1118 strain used for transgenesis and the population replacement 
experiments described above. Thus, while evidence for population replacement was 
obtained in both sets of experiments they are not strictly comparable in the sense that 
more variables have been changed than just the status of the w gene (w1118 versus w+).  
 
Embryo and adult viability determination: 
Adult viability for the crosses presented in Table 1 and Table 2 was determined as 
follows. 50 adult males of the indicated genotype were allowed to mate with 50 virgin 
females in bottles supplemented with dry yeast for three days. 10 bottles were established 
for each cross. Adults were then removed. Adult progeny from each bottle were 
collected, genotyped and counted (either directly or by weighing and comparing with a 
standard) for 10 days following eclosion of the first progeny. For embryo viability 
counts, 2-4 day old adult virgin females were allowed to mate with males of the relevant 
genotypes for 2-3 days in egg collection chambers supplemented with wet yeast paste. On 
the following day, a 3 hr egg collection was carried out, after first having cleared old eggs 
from the females through a pre-collection period on a separate plate for three hrs. 
Embryos were isolated into groups of 100 and kept on an agar surface at 25oC for 48-72 
hrs. The % survival was then determined by counting the number of unhatched embryos. 
Four groups of 100 embryos per cross were scored in each experiment, and each 
experiment was carried out three times. The results presented are averages from these 
three experiments. Embryo survival was normalized with respect to the % survival 
observed in parallel experiments carried out with the w1118 strain used for transgenesis. 
 
Modeling Medea population spread 
In order to model the spread of Medea and compare this with our experimental 
observations, a deterministic model was created. In this model, we used as our initial 
conditions 25% non-element-bearing (wildtype; WT) males, 25% homozygous Medea-
bearing males, and 50% WT females for Medea. These initial conditions, which mimic 
those of the first set of population cage experiments (green lines in Fig. 1E, F) are 
mathematically equivalent to the second set of crosses carried out, involving 
heterozygous Medeamyd88/+ males crossed to wildtype (+/+) females) (blue lines in Fig. 
1E, F),.  Genotypes for each generation were calculated beginning with genotype 
frequencies from the previous generation. We assumed random mating, nonoverlapping 
generations, and interfamily competition. We assume that maternal effect lethality for 
progeny of Medea that fail to inherit the element is 100%, as observed for Medeamyd88 
(Table 1). 
We kept track of the frequency of homozygous, heterozygous, and WT male and 
female flies in each generation. For this model, aside from the first generation, the 
frequency of WT males and females are equal, the frequency of heterozygous males and 
females are equal, and the frequency of homozygous males and females are equal. From 
the frequency of each type of fly, we calculated the frequency of each allele type. For 
example, in order to calculate the frequency of WT females in generation n+1 we begin 
with the frequency of WT females in generation n. We calculate the percent of the next 
generation that will be wild type by finding the frequency of viable WT female embryos 
normalized (divided by) the total viable population (WT, heterozygotes and 
homozygotes). WT female flies can arise from (½ WT males x WT females) + (1/4 of 
WT female x heterozygous males). WT embryos derived from crosses between 
heterozygous females x WT males will die as embryos and not contribute to the 
population. We calculate the total viable population by summing the WT females, WT 
males, heterozygous females, heterozygous males, homozygous females and homozygous 
males.   
When we assessed a fitness cost (as in Fig. 1C, D and Fig. S3), this cost was 
assumed to be an additive fitness cost. The fitness cost was expressed as a fraction of the 
embryos that die. That is, for a 5 percent fitness cost, 95 percent of the heterozygous 
embryos are viable, while 90 percent of the homozygous embryos were viable. For the 
model presented in Fig. S3, a specific additional fitness cost of 80% was incurred by 
progeny of homozygous Medeamyd88-int mothers that inherited only one copy of the 
element (the fathers being either Medeamyd88-int/+ or +/+). 
The formulas used are shown below. WTf, Hetf, Homof, WTm, Hetm, and 
Homom refer to the fraction of the adult population that is WT female, heterozygous 
female, homozygous female, WT male, heterozygous male, homozygous male, 
respectively. FitCost is the fitness cost, TotalViablePopulation=the total viable 
population, WTembryo, Hetembryo, HomoembryoWT embryo, and Hetembryo refer to 
the number of WT, heterozygous, and homozygous embryos produced before the effects 
of the medea element are included and without normalization.  All subscripts refer to the 
generation. 
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All model calculations were carried out in Excel for Windows XP. Matrix 
manipulation calculations were carried out in Maple 9.01 (Maplesoft, a division of 
Waterloo Maple Inc, 2003). 
 To determine if the experimental population data presented in Fig. 1 conformed to 
the model, the methods of Wilson (5) were used. Briefly, these methods are based on a 
Chi-square analysis of allele frequency corrected for the non-independence of generations 
(the frequency of allele p at generation 3 is dependent on the frequency of allele p (the 
Medea allele) in generation 2).  Because of the non-independence of generations, a 
covariation matrix is used.  The covariation matrix for a particular category (experimental 
trial), c, is denoted Wc and is calculated as  
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Nc,j is the number of genes (twice the number of individuals) taken at generation j to give 
be parents of the next generation.  nc,j is the number of genes (twice the number of 
individuals) used for genetic analysis.  To be conservative (that is, to make the 
assumption that our population has the largest possible variation), wc was calculated as 
(Vc)O,O/πC,O(l-πc,o), where Vc is the sample variance of the initial population and πC is the 
theoretical variance of the initial population. 
 
The difference vector, γcm, for any particular model, m, is calculated as the difference 
between the normalized gene frequencies observed experimentally and the normalized 
gene frequencies expected from our model using a particular fitness cost.  Each of these 
frequencies are normalized using the arcsin transformation: ( )p1sin*2 − , modified such 
that if p=0, the transform equals ⎟⎟⎠
⎞
⎜⎜⎝
⎛−
tn*2
1sin*2 1 , where nt is the number of individuals 
in a particular generation, t.  We calculate the Chi-square test statistic for a particular 
model, m, as (χm)2 =∑
c
( γcm)TWc-1 γcm.  The degrees of freedom in each category are 
calculated as the number of generations observed less the number of fitted parameters in 
the model.  To find the total degrees of freedom, the degrees of freedom in each category 
are summed. 
The values of p range from 0 (all individuals are homozygous for the construct) to 
1 (all individuals are homozygous wildtype). When all 7 experimental trials were 
considered as a group, the Chi-square test statistic for no fitness cost was 88.3. 
There are 122 degrees of freedom, leading to a critical χ2=148.8, with a 
probability error threshold (P value) of 0.05. Our Chi-square value is less than the critical 
value, indicating the data from our experiments is not significantly different from the 
theoretical model. The minimal Chi-square value to the nearest percent occurs at 0 fitness 
cost. Due to the conservative nature of this test, the confidence interval is large. To the 
nearest 0.01, the fitness cost can range from -0.23 to 0.10 and be consistent with our 
observations at a P value of .05. This range is calculated by finding the first value 
resulting in a Chisquare value falling outside the critical value, 147.7 (d.f=121). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. S1. Embryos of Medeamyd88 mothers that fail to inherit Medeamyd88 have dorsal-
ventral patterning defects. (A) Cuticle preparation of an embryo from wildtype parents. 
Anterior is to the left, and dorsal is up. Rows of denticle belts are visible on the ventral 
side of the embryo. (B-D) Embryos from Medeamyd88/+ mothers. Ventral denticle belts are 
decreased in size (B) or largely absent (C,D), consistent with the dorsalization expected 
on loss of maternal Toll signaling.  
 
 
 
 
 
 
Figure S2. The population replacement behavior of Medeamyd88-1 is consistent with that 
of a Medea carrying little or no fitness cost. The frequency of the non-Medea-bearing 
chromosome (the + allele) is plotted over generations, from Fig. 1F. The black lines 
identify boundary conditions for a Medea with a fitness gain of 23% or a fitness cost of 
10%, values at which we would reject the hypothesis that Medeamyd88-1 conforms to the 
model. See SOM methods for details. 
 
 
 
Figure S3. Drive characteristics of a Medea elements with the fitness characteristics of 
Medeamyd88-int. Medea is modeled as being introduced into the population at an allele 
frequency of 25%, representing a scenario in which equal numbers of wildtype and 
homozygous Medea-bearing males are mated with wild, non-element- bearing females, as 
in Fig. 1C, D. (A) Frequency of individuals lacking Medea for an element in which 
progeny of homozygous Medea females that inherit only one copy of the Medea suffer an 
80% fitness cost (embryo mortality), in addition to either no fitness cost (red line), a five 
percent additive fitness cost (yellow line),  a 10 percent additive fitness cost (green line), 
a 15% additive fitness cost (blue line), or a 20% additive fitness cost (black line) over 
generations. (B) Frequency of the + allele (non-element bearing chromosome) for the 
populations described in (A). For a Medea that has a fixed, additive fitness cost (such as 
described in Fig. 1C, D), the frequency of non-Medea bearing chromosomes initially 
decreases rapidly, but slows and eventually reaches a stable equilibrium value. This is 
due to Medea-dependent selection against the non element-bearing chromosome, which 
is balanced by its increased fitness relative to that of Medea-bearing counterparts, as 
detailed by Wade and Beeman (13). In contrast, when the progeny of homozygous 
Medea-bearing females cannot be rescued by a single Medea, then the non-element 
bearing homolog comes under selective pressure that increases with the frequency of 
homozygous Medea-bearing females in the population. For situations in which the fixed 
additive fitness costs are modest (0-10%) this results in a more dramatic reduction of the 
non-Medea-bearing chromosome from the population. Medea elements with this 
characteristic may be useful for population replacement since the presence of two effector 
copies in each individual should also delay the re-appearance of disease carriers when the 
effector mutates to inactivity. 
 
 
 
 
 
 
 
Figure S4. Scheme for the generation of a stronger version of the bic promoter, and for 
the generation of a transcript carrying two miRNAs designed to silence maternal myd88. 
See SOM methods for details. (A) Generation of a stronger bic promoter. (A, top) 
PrimersBic 5'Xho1 and Bic 3' EcoR1 were used to amplify the bicoid promoter. (A, 
middle) This fragment was re-amplified with Bic 3' EcoR1 and a second 5' primer (4 Bic 
5' Xho1) which included a dimer of Sry binding sites. (A, bottom) The final product, 
which carries an Xho1 site at the 5' end, and an EcoR1 site at the 3' end, constitutes the 
modified bicoid promoter. (B) The Drosophila miRNA mir6.1 stem-loop precursor and 
surrounding sequences is illustrated to the left, with the mature miRNA indicated in red. 
Processing sites for Drosha and Dicer are indicated (arrows). 22bp sequences 
corresponding to mature mir6.1 were replaced with sequences perfectly complementary 
to sequences from the myd88 5’UTR, generating two new miRNAs, mir6.1-myd88-1 
(shown) and mir6.1-myd88-2. Mature mir6.1-myd88-1 and mir6.1-myd88-2 are indicated 
in red, and complementary Myd88 mRNA sequences targeted by these miRNAs are 
indicated in black. (C) Strategy for the synthesis of mir6.1-myd88-1 using two rounds of 
PCR. The first round of PCR amplifies the miRNA stem loop (miRNA and miRNA* 
strand indicated in pink and yellow, respectively). This product was amplified in a second 
round of PCR using oligonucleotides that provide mir6.1 flanking sequences (not shown) 
and restriction sites for cloning. (D, upper) Schematic of the sequences that make up the 
bic-driven miRNAs that target myd88. Cloning sites are indicated. (D, lower) Stem loop 
regions and surrounding sequences of bic-mir6.1-myd88-1 + myd88-2. The bic promoter 
is located to the left. 
 
 
Figure S5. Schematic depicting key intermediates in the generation of a P element 
expressing myd88-silencing miRNAs under the control of the maternal bic promoter, and 
a miRNA-insensitive version of myd88 under the control of the transient, early bnk 
promoter. See SOM methods for details. 
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